Cargando…
Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
We evaluated the efficacy and safety of weekly paclitaxel plus trastuzumab as firs-tline chemotherapy in women with HER2-overexpressing metastatic breast cancer (MBC), and we investigated the prognostic factors including magnitude of HER2/neu amplification in this population. We analyzed 54 patients...
Autores principales: | Han, Hye-Suk, Kim, Jin-Soo, Park, Jin Hyun, Jeon, Yoon Kyung, Lee, Keun-Wook, Oh, Do-Youn, Kim, Jee Hyun, Park, So Yeon, Im, Seock-Ah, Kim, Tae-You, Park, In Ae, Bang, Yung-Jue |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2752777/ https://www.ncbi.nlm.nih.gov/pubmed/19794992 http://dx.doi.org/10.3346/jkms.2009.24.5.910 |
Ejemplares similares
-
PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017) -
Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
por: Seo, An Na, et al.
Publicado: (2016) -
Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017) -
HER-2/neu oncogene: what does amplification mean?
por: Pavy, J. J., et al.
Publicado: (1993) -
Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)